Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML).

Trial Profile

Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 May 2016

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Fludarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.
    • 02 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top